

1 **KMT2C knockout generates ASD-like behaviors in mice.**
2

3 Bastian Brauer, Nicolas Merino-Veliz, Constanza Ahumada, Gloria Arriagada, Fernando J
4 Bustos.

5 Institute of Biomedical Sciences, Faculty of Medicine and Faculty of Life Sciences, Universidad
6 Andres Bello, Santiago, Chile

7 *Correspondence should be addressed to: fernando.bustos@unab.cl
8
9

10 **ABSTRACT.**

11 Neurodevelopmental disorders have been associated with genetic mutations that affect cellular
12 function, including chromatin regulation and epigenetic modifications. Recent studies in humans
13 have identified mutations in KMT2C, an enzyme responsible for modifying histone tails and
14 depositing H3K4me1 and H3K4me3, as being associated with Kleefstra syndrome 2 and autism
15 spectrum disorder (ASD). However, the precise role of KMT2C mutations in brain disorders
16 remains poorly understood. Here we employed CRISPR/Cas9 gene editing to analyze the effects
17 of KMT2C knockout on animal behavior. Knocking out KMT2C expression in cortical neurons and
18 the mouse brain resulted in decreased KMT2C levels. Importantly, KMT2C knockout animals
19 exhibited repetitive behaviors, social deficits, and intellectual disability resembling ASD. Our
20 findings shed light on the involvement of KMT2C in neurodevelopmental processes and establish
21 a valuable model for elucidating the cellular and molecular mechanisms underlying KMT2C
22 mutations and their relationship to Kleefstra syndrome 2 and ASD.

23
24 **KEYWORDS:** ASD, KMT2C, Epigenetics, CRISPR/Cas9, Behavior
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **INTRODUCTION.**

51
52 Neurodevelopmental disorders are characterized by impairments in brain development that
53 consequently affect behavior, social interactions, communication, cognitive function, and learning
54 abilities, having a significant impact on the life of individuals. Among neurodevelopmental
55 disorders is Kleefstra syndrome 2 that is characterized by intellectual disability, facial
56 dysmorphisms, and autism spectrum disorders (ASD) (Koemans et al., 2017). ASD is a highly
57 variable condition characterized by deficits in social interactions and communication, repetitive
58 behaviors, and restricted interests, which may be associated with comorbid psychiatric,
59 neurological, physical, and/or intellectual disabilities (Lord et al., 2020). Genetic mutations are a
60 prominent factor contributing to the development of ASD. These mutations can lead to the loss of
61 function in a diverse array of genes, resulting in disrupted gene function through mechanisms
62 such as alterations in the reading frame or the creation of premature termination codons (Iossifov
63 et al., 2012; O’Roak et al., 2012; Rubeis et al., 2014; Satterstrom et al., 2020; Tuncay et al., 2022).
64 According to the SFARI GENE database, to date, there are more than 1392 genes associated to
65 ASD that are distributed in all human chromosomes (Banerjee-Basu and Packer, 2010). These
66 genes have many different functions in the cell including neuronal communication, cytoskeleton
67 formation and dynamics, and chromatin regulation and control of gene expression (Iossifov et al.,
68 2012; Rubeis et al., 2014; Stessman et al., 2017; Grove et al., 2019; Ruzzo et al., 2019;
69 Satterstrom et al., 2020). Among chromatin regulating genes, studies using transgenic animals
70 knock-out (KO) for the epigenetic enzymes CHD8, KDM6A or KDM6B show complex behavioral
71 phenotypes that resemble what is observed in humans carrying the mutations in them (Platt et
72 al., 2017; Tang et al., 2017; Gao et al., 2022), establishing model systems to study molecular and
73 cellular mechanisms underlying ASD.

74 Among the enzymes that control gene expression by chromatin remodeling, and more specifically
75 by altering histone tail modifications is KMT2C also known as MLL3 (Koemans et al., 2017;
76 Eshraghi et al., 2018; Faundes et al., 2018; Satterstrom et al., 2020). KMT2C is a histone lysine
77 methyltransferase enzyme that deposits the H3K4me1 mark, associated with active enhancers,
78 or the H3K4me3 mark related to transcriptionally active regions (Ruthenburg et al., 2007; Jozwik
79 et al., 2016). KMT2C belongs to the COMPASS complex that contributes to essential functions in
80 eukaryotic developmental signaling pathways (Fagan and Dingwall, 2019; Lavery et al., 2020;
81 Cenik and Shilatifard, 2021). Using fruit flies it has been shown that KMT2C binds to promoter
82 regions of genes involved in neuronal processes, and its loss of function produce severe deficits
83 in memory formation (Koemans et al., 2017). In humans, mutations in KMT2C have been found
84 in individuals with intellectual disabilities including Kleefstra syndrome 2 and ASD (Iossifov et al.,
85 2012; Stessman et al., 2017; Lavery et al., 2020; Satterstrom et al., 2020; Dhaliwal et al., 2021;
86 Siano et al., 2022; Tuncay et al., 2022; Zhou et al., 2022). Interestingly only eleven patients have
87 been described with mutations in KMT2C (Siano et al., 2022), with only one long term report
88 showing long lasting phenotypes (Wu and Li, 2022). Thus, phenotypes associated to KMT2C
89 mutants have not been fully characterized.

90 In this study, we utilized the CRISPR/Cas9 system to generate KMT2C KO models in both
91 cultured cells and mice to investigate the phenotypic consequences of KMT2C loss of function.
92 Using adeno-associated viruses (AAV) as delivery vectors we targeted exon 3 of KMT2C to
93 produce the KO of the gene. As expected, KMT2C KO produced a decrease in the abundance of
94 H3K4me1 and H3K4me3 histone tail marks in cultured neurons. In KMT2C KO mice, we
95 conducted a series of behavioral tests and observed deficits in social interaction, absence of
96 anxiety-like behavior, increased repetitive behaviors, and significant impairments in memory
97 formation.

98 These phenotypic changes are relevant to the human conditions of ASD and Kleefstra Syndrome
99 2, both of which are associated with neurodevelopmental disorders that can be attributed to the
100 loss of function of KMT2C. Our findings demonstrate the utility of the CRISPR/Cas9 technology

101 to generate an animal model of KMT2C KO that can be used to investigate the cellular and
102 molecular mechanisms underlying the pathogenesis of KMT2C knockout-mediated disorders.
103
104

105 **Materials and Methods**

107 **Primary neuronal cultures.**

108 Postnatal day 0 Cas9 KI mice (C57BL/6J; JAX 026179) were euthanized by decapitation and the
109 whole brain was extracted in ice cold Ca²⁺/Mg²⁺-free Hank's balanced salt solution (HBSS).
110 Meninges were removed, the tissue was minced and incubated with Papain (20 U) for 15 minutes
111 at 37°C. Cells were rinsed twice with HBSS, resuspended by mechanical agitation through fire-
112 polished glass Pasteur pipettes of decreasing diameters, and plated over poly-L-lysine-coated
113 culture plates or cover slips. Cultures were maintained at 37 °C in 5% CO₂ in growth media
114 [Neurobasal-A (Life technologies 1088802) supplemented with B27 (Life technologies 17504044),
115 2 mM L-glutamine (Life technologies 25030-081), 100 U/ml penicillin/streptomycin (Life
116 technologies 15070-063)]. Half of the media was replaced every 3 days. Neuronal cultures were
117 transduced at 3 days in vitro (DIV) using concentrated AAV particles.
118

119 **Plasmids.**

120 For the expression of CRISPR/Cas9, plasmids were generated in AAV backbones. For sgRNAs
121 20nt target sequences were selected contiguous to a 5'-NGG photospacer-adjacent motif (PAM).
122 sgRNAs for KMT2C were designed against exon 3 (K1: 5' GGAAATCAAAGAACAAATCTG 3'; K2:
123 5' GGAGGATGCTGAAACAGAAG 3') and cloned into a custom AAV plasmid under the control
124 of the U6 promoter, and coding for tdTomato under the control of the human synapsin1 promoter.
125 For viral packaging we used a plasmid coding for the PHP.eB capsid and pAdDeltaF6 plasmid to
126 express adenovirus E4, E2A and VA genes. pUCmini-iCAP-PHP.eB was a gift from Viviana
127 Grdinaru (Addgene plasmid # 103005 ; <http://n2t.net/addgene:103005> ;
128 RRID:Addgene_103005), pAdDeltaF6 was a gift from James M. Wilson (Addgene plasmid #
129 112867 ; <http://n2t.net/addgene:112867> ; RRID:Addgene_112867).

130 **AAV Production**

131 AAV particles coding for sgRNA against KMT2C under the control of a U6 promoter, together with
132 the red fluorescent protein tdTomato controlled by the hSyn1 promoter were packed using the
133 PHP.eB capsid (Bustos et al., 2017, 2023; Chan et al., 2017). High titer viral particles were
134 purified as described in (Challis et al., 2019). Briefly, HEK 293T were transfected with PEI and
135 PHP.eB capsid plasmids, the vector with KMT2C sgRNA-tdTomato, and the helper plasmid DF6.
136 After 24 h of transfection, the media was replaced for DMEM 1% FBS. 72 h later, medium was
137 collected from the plates and replaced with fresh DMEM 1% FBS. The collected medium was
138 stored at 4°C. To collect the viruses, 120 h after transfection, the cells were detached from the
139 plate and transferred to 250 mL conical tubes, as well as the collected media. They were
140 centrifuged for 10 min at 2000 g, the supernatant was removed and saved for later use. The pellet
141 was resuspended in SAN digestion buffer (5 mL of 40 mM Tris, 500 mM NaCl and 2 mM MgCl₂
142 pH 8.0) containing 100U/mL of Salt Active Nuclease (SAN) from Arcticzymes and incubated at
143 37°C for 1 h. To the supernatant that was saved, a 5x stock solution of 40% PEG 8000 (Sigma)
144 in 2.5M NaCl was added, incubated on ice for 2 h and centrifuged at 4000 g for 30 min in 250 mL
145 bottles. The supernatant was collected and was placed in an Optiprep gradient and
146 ultracentrifuged at 41.000 rpm for 4 h. The phase containing the AAV was rescued and frozen at
147 -80°C for later use.
148

149

150 **Genomic DNA extraction and T7 endonuclease I assay.**
151 Genomic DNA from transduced primary cortical neurons or brain tissue from transduced animals
152 was extracted using Quick-DNA Miniprep Kit (Zymo Research, USA) following manufacturer
153 recommendations. To test KMT2C edition, PCR with primers encompassing the edited region (5'
154 TACGTTGACCTCAAGGCACAGT 3', 5' TAAAAACTGTCTCTGGCCCCCG 3') were used to
155 determine edition of the locus. PCR products were run in agarose gels and purified by Gel
156 extraction kit (Qiagen). 400ng of gDNA was used for T7 endonuclease assay (NEB Cat#M0302).
157 Assays were run in TBE polyacrylamide gels and visualized using Gel Red.
158

159 **RNA extraction and RT-qPCR**
160 RNA was isolated from the tissues and cell cultures using TRIzol (Life Technologies) according
161 to the manufacturer's instructions as in (Henriquez et al., 2013; Bustos et al., 2017, 2023). To
162 obtain complementary DNA (cDNA), 400 ng of RNA was used. cDNA quantification was
163 performed by qPCR using 3 µL of the cDNA mix, 6 µL Fast Evagreen qPCR Master Mix (Biotium,
164 31003), 2 µL of nuclease-free water, and 1 µL of 10 mM primers with the program recommended
165 by the maker. The relative abundance was measured by the ddCt method using the GAPDH gene
166 as a control. Transcript detection was performed with specific primers for messenger RNA
167 (mRNA): KMT2C: Fw 5' TGTTCACAGTGTGGTCAATGTT 3'; Rv 5'
168 GAGGGTCTAGGCAGTAGGTATG 3'; GAPDH: Fw 5' ATGGTGAAGGTCGGTGTGAA 3'; Rv 5'
169 CATTCTCGGCCTTGACTGTG 3'.
170

171 **Nuclear protein extraction**
172 Nuclear proteins to determine histone tail modification by western blot were isolated as in
173 (Henriquez et al., 2013). Briefly, cultured cells were washed with cold PBS, centrifuged at 5000
174 rpm for 5 min and the pellet was resuspended in 5 volumes of cell lysis buffer (50 mM Hepes pH
175 7.9, 3 mM MgCl₂, 20 mM KCl, 0.1% NP-40, 1 mM DTT and Protease Inhibitor Cocktail) and
176 incubated on ice for 10 min. Solution was homogenized with 30 strokes of the pestle and
177 centrifuged at 6000 rpm for 15 min at 4 °C to separate the cytosolic and nuclear fractions. The
178 pellet was resuspended in 1 volume of Buffer C (10 mM Hepes pH 7.9, 420 mM NaCl, 1.5 mM
179 MgCl₂, 25% Glycerol, 0.2 mM EDTA, 1 mM DTT and protease inhibitor cocktail) and incubated
180 for 1 hour. Extracts were sonicated at 50% amplitude in cycles of 30 s ON/ 30 s OFF, centrifuged
181 at 12,000 rpm for 15 min at 4 °C. Supernatant was recovered and frozen at -80 °C to be
182 subsequently quantified by Bradford.
183

184 **Western blot analysis.**
185 Nuclear fractions were separated on polyacrylamide gels and transferred to PVDF membranes
186 (Millipore, USA). Membranes were blocked and incubated overnight at 4C with primary
187 antibodies. After rinsing, the membranes were incubated with secondary antibodies for 30 min at
188 room temperature, rinsed and developed using chemiluminescence (Cell Signaling Technology,
189 USA). Primary antibodies used: H3K4me1 (Diagenode, C15410194), H3K4me3 (Diagenode,
190 C15410003), and H3pan (Diagenode C15410324) as loading control. For detection HRP-
191 conjugated secondary anti-bodies were used (Cell Signaling Technology, USA).
192

193 **Animals**
194 All animal procedures and experiments were performed according to the NIH and ARRIVE
195 guidelines and were approved by the animal ethics committee from Universidad Andrés Bello
196 (020/2018). Newborn Cas9 KI mice (C57BL/6J; JAX 026179) were cryoanesthetized in a cold
197 aluminium plate and injected with 1 µL of concentrated AAV (1x10¹¹ vg), containing sgRNA or
198 empty vector, in each cerebral ventricle at a depth of 3 mm in the animal's head at 2/5 of the

199 intersection between lambda and the eye with a 10 μ L HAMILTON syringe (Hamilton, 7653-01)
200 and a 32 G needle (Hamilton, 7803-04). After the injection, P0 mice were placed in a heating pad
201 until they recovered their color and temperature, then they were returned to their cage with the
202 mother (Passini and Wolfe, 2001; Kim et al., 2014). 3 weeks after birth, mice from both conditions
203 were weaned off and separated by sex in cages with a 12/12 light/dark cycle with free access to
204 food and water. A chip (p-chips, Pharmseq) was put in the tail of each animal for easy tracking
205 during behavioral test. Behavior tests were performed between 9:00 am and 6:00 pm. At the end
206 of the battery of behavioral tests, the animals were euthanized using isoflurane for subsequent
207 molecular analyses.

208

209 **Behavioral overview**

210 All behavioral tests on mice were carried out 8 weeks after AAV injection. Before each test, mice
211 cages were transported to the behavior room and habituated for 30 min in the dark. After
212 completing a test, equipment and devices used were cleaned with 70% ethanol. Tests were
213 recorded and analyzed with ANY-Maze software and/or Graphpad Prism software.

214

215 **Rotarod:** Motor coordination and capacity was assessed in the Rotarod test. Mice were placed
216 on an elevated accelerating rod for three trials. Each trial lasted for a maximum of 3 min, during
217 which the Rotarod underwent a linear acceleration of 4 rpm per min. Mice weights were registered
218 before the test. Mean time and speed from each animal were registered before falling off.

219

220 **Open Field:** Mice were tested in an open field (45 \times 45 cm) virtually divided into central and
221 peripheral regions with ANY-Maze software. Apparatus were illuminated from above with 300 lux
222 in center and 250 lux in periphery. Animals were allowed to roam freely for 10 min. The total
223 distance traveled and time in center and periphery were analyzed.

224

225 **Light and Dark:** The apparatus used for this test is a 40 cm box split in half with 390 lux on light
226 side and 0-2 lux on the dark side. Mice were placed in the dark chamber and were allowed to
227 freely explore both chambers for 10 min. Distance traveled, time spent and number of entrances
228 to the light side were analyzed.

229

230 **Elevated zero-maze:** The apparatus consisted of a 46 cm diameter circular runway and raised
231 54 cm off the ground. The runway was divided equally into four alternating quadrants of open arcs
232 and closed arcs, with 15 cm walls. Mice started in the center of an open arm and were recorded
233 by video tracking for 10 min. Measures of cumulative open and closed arc times, total open arm
234 entries, distance in each arm and total distance traveled were analyzed.

235

236 **Marble burying test:** Mice were tested in a 45 x 45 cm box filled with 5 cm deep wood chips and
237 49 marbles distributed in a 7x7 pattern. Animals were placed in the test cage and allowed to
238 explore and bury the marbles during a 30 min session that was videotaped. At the end of the
239 session the subject was removed and the number of marbles buried (2/3 marble covered by wood
240 chip) was counted.

241

242 **Contextual fear conditioning:** UGO-BASILE apparatus controlled by ANY-Maze was used. This
243 equipment consisted of a sound attenuating box, fan, light (visible/I.R.), a speaker, a USB camera,
244 a single on-board controller, and a mouse cage. All trials were recorded and all mice underwent
245 a habituation, conditioning and testing phase (Pandian et al., 2020; Bustos et al., 2023). In the
246 habituation (day 1): mice were placed in the fear conditioning cage to explore freely for 5 min and
247 then returned to their cage. During the conditioning phase (day 2): subject mouse was placed in
248 the fear conditioning cage, let explore freely for 2 min and then subjected to an electric shock of
249 0.75 mA for 2 s. It was allowed to explore freely for 3 min and returned to its cage. On the test

250 phase (day 3): Twenty-four hours after the conditioning phase, the animals were tested for
251 contextual memory. Each mouse was placed in the fear conditioning box, allowed to freely explore
252 for 5 min, and returned to its cage. The number of freezing episodes and freezing time was
253 registered.

254
255 **Barnes Maze:** A non-reflective gray circular platform (91 cm diameter) with 20 holes (5 cm
256 diameter) evenly distributed along the perimeter, with one hole containing a metal escape tunnel
257 was used. Three exogenous visual cues (length/width ~30 cm) were used around the platform:
258 black circle, blue triangle and a yellow square. The light was adjusted to 1000 lux in the center of
259 the platform. All animals underwent a phase of habituation, spatial acquisition and testing (Pitts,
260 2018; Sunyer et al., 2007). For habituation (day 1): each mouse was placed in the center of the
261 platform, directed towards the escape hole, and allowed to remain there for 1 min. Then it was
262 taken and allowed to freely explore the maze for 5 min, and was again allowed to spend 1 min
263 inside the escape hole. If the mouse did not enter within 5 min, it was gently guided near the
264 escape hole selected randomly on the table. During training phase (day 2-4): each animal was
265 introduced into the start box, left in the center of the platform for 10 s and the start box was
266 removed, and simultaneously a 16,000 Hz sound was played. The test ended at 3 min or when
267 the mouse has found the escape hole. This procedure was repeated 2 times per day. During
268 those days the following was recorded: Primary latency: Time to review the escape hole for the
269 first time; Time in the zone of interest; Total distance traveled. In the test phase (day 5): the
270 position of the escape tunnel was changed, and the animal was brought in the start box to the
271 center of the platform, left for 10 s and sound reproduction was started. The test ended at 90 s or
272 when the mouse found the escape tunnel. The number of primary and total errors, primary and
273 total latency, and total distance before finding the gap were recorded. The number of visits to
274 each hole was also measured to show preference.

275
276 **Three-Chamber Sociability and Social Novelty Test:** This was performed in a transparent
277 acrylic three-chambered apparatus with the following dimensions: 61.5 x 43.5 x 22 cm. Each outer
278 chamber was 20 x 43.5 cm. We used small cages of 8 cm diameter and 18 cm height to put the
279 social (unknown WT mice of the same sex and similar age) and non social stimulus (plastic block
280 of 8 x 4 x 4 cm). A 20 lux illumination was used in this test. On the habituation phase (day 1):
281 stimulus holders were placed in the center of outer chambers. The subject mouse was placed in
282 the central chamber and allowed to explore freely for 10 min. Apparatus and stimulus holders
283 were cleaned between mice with 70% ethanol. During pre-test (day 2): two clean paper balls were
284 prepared and introduced inside each stimulus holder. The mouse was placed in the central
285 chamber and allowed to explore freely for 10 min. Apparatus and stimulus holders were cleaned
286 between mice with 70% ethanol. For the social preference test (day 3): a wild-type mouse was
287 placed in a stimulus holder to be used as a social stimulus and changed for another one every 2
288 test runs to avoid burnout or social fatigue (Rein et al., 2020). A plastic block was placed in the
289 stimulus holder as a non social stimulus. Once social and non social objects were put in the outer
290 chambers, mouse was placed in the central chamber and allowed to explore freely for 10 min.
291 Behavior was video recorded. Time amount and distance traveled in the social and non social
292 chamber was registered, as well as the interaction time with each stimulus.

293
294 **Social Interactions:** In this test, an animal from the control condition or KMT2C KO with a wild
295 type animal of the same sex and similar age, were placed in a 30x30x30 cm box for 10 min.
296 Aggressive behavior (e.g. biting, mounting or aggressive grooming) and the amount of social
297 interactions (nose-nose sniffing, nose-face, nose-anogenital area, and grooming) between them
298 were quantified.

299

300 **Tube dominance:** Tube test apparatus consisted of a smooth transparent acrylic tube of 30 cm
301 length and internal diameter of 2.5 cm. Mice were habituated for 3 days. On day 1, each animal
302 interacted and explored the tube freely for 30 min and was then returned to its cage where a
303 habituation tube was placed with a 10 cm length with an internal diameter of 2.5 cm. A small
304 amount of gel food (Diet Gel Boost) was placed at the end of the cage habituation tube and they
305 were deprived of their common diet food. On day 2, tube inlet was closed and gel food was placed
306 at the end. Animals were allowed to explore freely for 30 min. They were fed and starved again
307 of their common diet for 12h and a small amount of gel food (Diet Gel Boost) was placed at the
308 end of the cage habituation tube. On day 3, the same procedure of Day 2 was repeated, and mice
309 were returned to their common diet. On the training phase (day 4 and 5): mice were taken by the
310 tail and allowed to freely explore for approximately 1 min on the table where the tube was located.
311 Then they were taken from the tail and put on one end of the tube and when the animal entered
312 the tail, it was released. If the animal did not move for several seconds, it was gently prodded with
313 a wooden stick. This step was repeated 5 times per side, so that the mouse passed through the
314 tube a total of 10 times. The same procedure was repeated on day 4 and 5. On the test phase
315 (day 6-9): two mice, one control and one KMT2C KO, were taken and brought to the ends of the
316 tube by the tail. When they entered completely and reached the middle of the tube, their tails were
317 released to begin the confrontation. The test was repeated for 4 days. The mouse that pushes and
318 removes its opponent from the tube was considered the winner and the one that is removed from
319 the tube was considered the loser. All confrontations were video recorded to analyze the times
320 each animal won and lost. The test stopped when the loser had all 4 paws out of the tube. The
321 total number of wins and the number of wins per day were compared between control and KMT2C
322 KO conditions.
323

324 **Brain sectioning and mounting.**

325 After behaviors to assess brain transduction, animals were deeply anesthetized, and half of the
326 brain was extracted and fixed by immersion PBS + 4% PFA + 4% Sucrose into 30 mL flasks for
327 24 h. After fixation, a Leica VT1000s vibratome was used to cut 100 μ m coronal sections. Slices
328 were kept in PBS and mounted using Fluoromont G (EMS, Hatfield, PA) to preserve the
329 fluorescence signal. Brain images were captured with a Nikon Eclipse TE2000 epifluorescence
330 microscope (Nikon, USA).

331 **Statistical analysis**

332 Values are presented as mean \pm standard error of mean (SEM) for 3 or more independent
333 experiments. Statistical analyzes with Student's t-test was performed. Values of $p < 0.05$ were
334 considered statistically significant. All statistical analyzes were performed using Graphpad Prism
335 (GraphPad Software Inc.).
336

337

338 **RESULTS**

339

340 **Gene editing of KMT2C results in knockout in primary culture of cortical neurons and in** 341 **the mouse brain.**

342 To determine the role of KMT2C in the induction of ASD-like behaviors, we used CRISPR/Cas9
343 technology to knock out gene expression (Cong et al., 2013; Swiech et al., 2014). First, we
344 designed sgRNAs targeting the coding sequence of KMT2C. We targeted exon 3 of the gene
345 since it is a common exon for all splice variants (Figure 1A). Cortical neuron cultures of Cas9 KI
346 mice were transduced using AAVs coding for TdTomato alone as a control or together with sgRNA
347 K1 or K2. Ten days after transduction, genomic DNA was extracted, and the T7 endonuclease I
348 assay was performed. We observed that both sgRNAs targeting KMT2C exon 3 were able to edit
349 the genomic locus, shown by the smaller size DNA bands (Figure 1B). Additionally, total RNA

350 was extracted, and RT-qPCR was performed to determine changes in KMT2C expression. We
351 observed that both K1 and K2 sgRNAs significantly reduced KMT2C expression by more than
352 60% in primary cortical neurons (Figure 1C). KMT2C is a component of the COMPASS chromatin
353 remodeling complex that can increase the histone tail modifications H3K4me1 and H3K4me3 at
354 enhancers and promoters to induce gene expression (Jozwik et al., 2016). Therefore, we tested
355 the presence of these histone tail marks in nuclear extracts of transduced cortical neurons. We
356 found that the transduction of neurons with K1 or K2 decreased the total abundance of H3K4me1
357 and H3K4me3 (Figure 1D). This data was quantified showing a significant reduction in the relative
358 expression over H3 of both H3K4me3 (Figure 1E) and H3K4me1 (Figure 1F). This data shows
359 that the CRISPR/Cas9 system can edit the KMT2C genomic locus, reduce its expression, and
360 decrease the presence of histone tail modifications associated with its function in KMT2C KO
361 cultured neurons.

362 In humans, loss-of-function mutations in KMT2C have been associated to the appearance of
363 ASD-like behaviors and Kleefstra syndrome 2 (Koemans et al., 2017; Satterstrom et al., 2020;
364 Siano et al., 2022; Wu and Li, 2022), however limited information is available about the phenotype.
365 To determine whether KO of KMT2C in mice can produce ASD-like behaviors, we used AAVs to
366 express the previously characterized K2 sgRNA in Cas9 knock-in animals. We selected K2
367 sgRNA from our culture experiments because it showed a more significant reduction in mRNA
368 expression compared to control neurons and K1 (Figure 1C). The fluorescence reporter
369 TdTomato was used to show transduction efficiency. AAVs were packed using the PHP.eB capsid
370 (Chan et al., 2017) to efficiently transduce the whole brain after injection into the cerebral
371 ventricles of P0-P1 animals (Bustos et al., 2023). At eight weeks, animals were subjected to
372 behavioral testing. To be included in the final behavioral analyses, animals needed to meet three
373 parameters after euthanizing and dissecting their brains: 1) a strong fluorescence signal widely
374 spread in the brain (Figure G); 2) the T7 endonuclease I test showed gene editing (Figure 1H);
375 and 3) RT-qPCR analyses showed a >50% reduction in KMT2C expression levels (Figure 1I). A
376 total of 9 animals met these criteria, and the following results for KMT2C CRISPR injected animals
377 (henceforth KMT2C KO mice) are only based on these 9 animals and 15 animals used as control.
378 Fluorescence imaging of brain sections, show high and broad expression of tdTomato (Figure G).
379 All KMT2C KO (KO1-9) animals show lower size bands in the T7 endonuclease I assay, showing
380 that gene editing was successful (Figure 1H, KO1-9) compared to 5 representative control
381 animals (Figure 1H, Control 1-5). In addition, RT-qPCR from brain tissue showed >50% reduction
382 in the expression levels of KMT2C in injected animals (Figure 1I). These results demonstrate that
383 CRISPR/Cas9 system can edit the KMT2C genomic locus and reduce its expression in the mouse
384 brain.

385
386 **KMT2C KO animals exhibit no signs of behaviors associated with anxiety.**
387 Eight weeks after injection, KMT2C KO and wild-type littermate (Control) animals underwent
388 behavioral testing. Importantly, KMT2C knockout did not result in any discernible differences in
389 growth. To assess whether KMT2C KO animals had any locomotion deficits that could impact
390 their performance in the upcoming battery of behavioral tests, the rotarod test was performed.
391 KMT2C KO animals did not exhibit any locomotion difficulties compared to their wild-type
392 littermates, as both groups spent similar amounts of time on the rotarod apparatus (Figure 2A).
393 One of the hallmarks of both human and animal ASD cases is the manifestation of anxiety-like
394 behaviors (Silverman et al., 2010; Lord et al., 2020; Pandian et al., 2020; Bustos et al., 2023). To
395 assess whether knockout of KMT2C could produce similar behaviors in mice, we subjected
396 KMT2C KO animals to behavioral analyses after 8 weeks. In the open field test, animals were
397 allowed to explore for 10 min, and the time spent in the center or periphery of the apparatus and
398 the distance traveled was measured (Figure 2B). We observed no significant differences between
399 KMT2C knockout animals and control littermates in total distance traveled (Figure 2C), time spent
400 in the center (Figure 2D), or time spent in the periphery (Figure 2E). However, we when we looked

401 in more detail at the time spent in the center, we found significant reduction in the distance
402 travelled in the center by KMT2C KO animals (Figure 2F), suggesting appearance of anxiety since
403 animals freeze in the zone.

404 Then animals were tested in the light-dark apparatus, where they were placed in the dark chamber
405 and allowed to explore for ten minutes. We observed no significant difference in the number of
406 crosses to the light compartment (Figure 3A) or time spent in the illuminated field (Figure 3B).
407 Similarly, in the elevated zero maze, KMT2C KO animals did not differ significantly from wild-type
408 littermates in the time spent in the open zone (Figure 3C) or distance traveled (Figure 3D) after
409 exploring the platform for ten minutes. Finally, to determine whether KMT2C KO animals showed
410 signs of anxiety or repetitive behavior, we used the marble burying test, in which KMT2C KO and
411 Control animals were placed in a box with 49 marbles to be buried in a thirty-minute interval. We
412 found that KMT2C KO animals buried more marbles than Control littermates within the given
413 timeframe (Figure 3E). Taken together, our data show that KMT2C KO animals exhibit repetitive
414 behaviors, as observed in the marble burying test, and display almost no signs of anxiety-like
415 behaviors that could be measured using these behavioral tests.

416

417 **KMT2C KO animals show impaired social behaviors.**

418 Individuals with ASD often exhibit difficulties in social interaction, which can manifest as a lack of
419 aptitude or skill in performing social interaction (Silverman et al., 2010; Lord et al., 2020). To
420 assess the ability of KMT2C KO mice to engage in social interaction, we employed the three-
421 chamber social interaction test leaving the animal to explore for ten minutes (V. et al., 2007; B. et
422 al., 2010; Pandian et al., 2020; Bustos et al., 2023). KMT2C KO and Control animals spent similar
423 time in the novel mouse region (NM) (Figure 4A) and novel object region (NO) (Figure 4B).
424 However, when the time spent directly interacting with NM or NO was analyzed in more detail, we
425 found that KMT2C KO animals spent significantly more time engaging directly with the NM (Figure
426 4C) and NO (Figure 4D) than their wild-type littermates. This suggests that KMT2C KO mice
427 exhibit alterations in social behavior compared to Control mice.

428 To gain insight into the social behavior observed, we used the social interaction test. Pairs of
429 animals of the same sex from KMT2C KO and Control animals were let to interact in a clear box
430 for 10 minutes and recorded to quantify interactions. The quantification of social sniffing in animal
431 pairs showed no significant difference in the frequency of nose-nose (N-N) interactions (Figure
432 5A) or nose-head (N-H) interactions (Figure 5B). However, we observed a significant decrease in
433 the number of nose-anogenital (N-A) interactions in KMT2C KO mice (Figure 5C), indicating a
434 decrease in social investigation activity. Additionally, we found that KMT2C KO animals displayed
435 a significant increase in self-grooming episodes compared to their wild-type littermates (Figure
436 5D). Lastly, we used the tube dominance test to determine social hierarchy and interaction among
437 animals. Results show that KMT2C KO animals won a significantly greater number of times
438 against wild-type animals in the test tube (Figure 5E). This data demonstrates that KMT2C KO
439 animals exhibit social impairments, as evidenced by a decrease in social investigation, an
440 increase in self-grooming episodes to avoid interactions, and avoidance of direct contact with
441 other animals. These behaviors suggest that KMT2C KO animals have difficulty engaging in social
442 interactions and may display aggression when faced with such situations.

443

444 **KMT2C KO mice exhibit severe memory formation deficits.**

445 Cognitive impairments are a crucial feature of ASD phenotypes. Human with mutations in KMT2C
446 have shown to have mild to severe intellectual disability, phenotype also associated to ASD
447 (Koemans et al., 2017; Siano et al., 2022; Wu and Li, 2022). To determine whether KMT2C KO
448 animals have impaired capacity to form memories, we utilized two behavioral tests. First, we
449 employed the contextual fear conditioning paradigm to analyze long-term memory formation after
450 24 hours. Animals were tested for five minutes, and we observed that KMT2C KO animals froze
451 for a significantly reduced amount of time compared to Control animals (Figure 6A). Next, we

452 used the Barnes maze apparatus to assess spatial learning and memory (Pitts, 2018; Gawel et
453 al., 2019). Similarly, to what is observed in the open field apparatus, no significant difference in
454 the total distance travelled between KMT2C KO and controls animals (Figure 6B). However, when
455 we quantified the primary latency - time to reach the escape hole for the first time - we observed
456 a significant increase in the time required by KMT2C KO animals, and some of them never
457 reached the escape hole (Figure 6C). Finally, to assess whether KMT2C KO animals showed
458 deficits in spatial memory, we moved the escape hole to a new location and quantified the time
459 spent in the region where the original escape hole had been located. We observed a significant
460 decrease in the time spent in the target region by KMT2C KO animals compared to Controls
461 (Figure 6D). Taken together, our data suggests that KMT2C KO animals exhibit reduced memory
462 formation capacity and significant cognitive impairments in both behavioral tests used.
463
464

465 **DISCUSSION.**

466 Neurodevelopmental disorders, including ASD and Kleefstra Syndrome 2, have been associated
467 with mutations in genes involved in chromatin regulation (Rubeis et al., 2014; Eshraghi et al.,
468 2018; Satterstrom et al., 2020; Chen et al., 2021; Siano et al., 2022). Some of these genes encode
469 enzymes responsible for modulating histone tail modifications, which play a crucial role in gene
470 expression regulation (Bannister and Kouzarides, 2011).

471 In this study, we utilized CRISPR/Cas9 technology to disrupt the expression of KMT2C, an H3K4
472 methyltransferase enzyme, both *in vitro* and *in vivo*. Our results demonstrate a significant
473 reduction in KMT2C expression *in vitro*, accompanied by a concomitant decrease in the overall
474 levels of H3K4me1 and H3K4me3, histone tail modifications associated with the function of
475 KMT2C (Shilatifard, 2012; Faundes et al., 2018). This reduction in histone tail marks indicates the
476 successful gene editing of KMT2C. Furthermore, the changes in these histone tail marks suggest
477 a mechanism by which KMT2C KO may impact gene networks involved in the observed
478 phenotype. To further elucidate these alterations, future ChIP-Seq experiments will be conducted
479 to examine changes in histone marks associated with promoters and analyze the specific genes
480 and gene networks involved in the manifestation of the phenotype.

481 In humans, studies have demonstrated a strong association between mutations in KMT2C and
482 carcinogenesis, highlighting the connection between epigenetic regulation and the development
483 of cancer (Fagan and Dingwall, 2019). However, the understanding of the impact of KMT2C
484 mutations on brain disorders remains limited. In humans, loss of function mutations of KMT2C
485 causes ASD and Kleefstra syndrome 2, characterized by intellectual disability and ASD-like
486 behaviors (Koemans et al., 2017). Only eleven cases of Kleefstra syndrome 2 have been reported
487 in literature, thus not much evidence on the behavioral phenotype is described (Koemans et al.,
488 2017; Chen et al., 2021; Siano et al., 2022; Wu and Li, 2022). Using AAV intracerebral ventricular
489 injections at postnatal day 1, we injected CRISPR/Cas9 to produce KMT2C KO. We observed a
490 robust decrease in the expression of KMT2C following gene editing *in vivo*, which enabled us to
491 investigate the behavioral changes associated with ASD. We subjected the animals to a battery
492 of test that are design to test ASD like behaviors (Pandian et al., 2020; Bustos et al., 2023). Similar
493 experiments have been conducted to characterize the behavioral phenotypes in mutant animals
494 for KMD6A and KMD6B (Tang et al., 2017; Gao et al., 2022). KMT2C KO animals did not show
495 signs of affected growth or locomotor abilities, thus effects on the posterior tests are not due to
496 locomotive problems. Using the open field test, light and dark apparatus, and elevated zero maze,
497 we did not observe significant differences in anxiety-related behaviors. This observation is
498 supported by the phenotypes observed in humans carrying KMT2C mutations where anxiety is
499 not described as a main characteristic of the individuals (Koemans et al., 2017; Grove et al., 2019;
500 Siano et al., 2022; Wu and Li, 2022). Repetitive behaviors are a recognized characteristic of ASD
501 phenotypes, as evidenced by studies conducted on other mouse models (Silverman et al., 2010;
502 Lord et al., 2020; Pandian et al., 2020; Bustos et al., 2023). To assess repetitive behaviors in

503 KMT2C KO animals, we employed the marble burying test and quantified grooming behaviors.
504 Our results indicate that KMT2C animals exhibit increased repetitive behaviors. While this specific
505 characteristic has not been described in humans with KMT2C mutations, it is important to note
506 that repetitive behaviors are complex and may be associated with the presence of comorbid
507 conditions such as attention-deficit/hyperactivity disorder (ADHD), as observed in individuals with
508 KMT2C mutations (Wu and Li, 2022).

509 In the social tests performed, KMT2C KO animals displayed increased social interactions and
510 demonstrated dominance over WT animals in the tube dominance test. While this specific
511 phenotype has not been described in humans due to limited available data, it highlights a novel
512 observation that warrants further investigation in individuals with KMT2C mutations. By exploring
513 this phenotype in human subjects with KMT2C mutations, we may gain valuable insights into the
514 role of KMT2C in social behavior and its potential implications for neurodevelopmental disorders.
515 Intellectual disability is a well-documented phenotype observed in all human patients with KMT2C
516 mutations, as supported by previous studies (Koemans et al., 2017; Siano et al., 2022; Wu and
517 Li, 2022). To determine whether KMT2C KO animals exhibit impairments in memory formation,
518 which is closely associated with intellectual disability, we conducted the fear conditioning and
519 Barnes maze tests. Results revealed severe deficits in memory formation in KMT2C KO animals,
520 with some individuals failing to learn the required tasks altogether. This finding aligns with the
521 phenotypes observed in humans with KMT2C mutations and suggests that KMT2C plays a critical
522 role in cognitive processes, including memory formation, thereby contributing to intellectual
523 disability.

524 To the best of our knowledge, this study represents the first comprehensive characterization of
525 the behavioral phenotype of KMT2C KO animals. Particularly, using CRISPR/Cas9 gene editing
526 we were able to KO KMT2C in the entire brain to assess the behavioral phenotype. The
527 phenotypic similarities observed between KMT2C KO animals and humans with KMT2C
528 mutations indicate the relevance and translational potential of our approach. This animal model
529 will allow to investigate the underlying cellular and molecular mechanisms involved in the
530 development of ASD and Kleefstra syndrome 2 associated with KMT2C mutations.

531 In summary, our study contributes to the understanding of KMT2C-related neurodevelopmental
532 disorders. In addition, the generated animal model offers a promising avenue for investigating
533 therapeutic interventions and advancing our knowledge of the molecular pathways involved in
534 ASD and Kleefstra syndrome 2.

535
536
537
538

539 **ACKNOWLEDGEMENTS.**

540 This work was supported by: ANID Fondecyt Iniciacion 11180540 (FJB), ANID PAI 77180077
541 (FJB), ANID-FONDECYT 1220480 to GA, UNAB DI-02-22/REG (FJB), DI-03-21/APP UNAB (BB).
542 We thank Lorena Varela-Nallar for critical reading of the manuscript and helpful feedback.

543
544
545
546
547
548
549
550
551
552
553

554

555 REFERENCES

556

557 B., D., Erwin, L., P., Brandon, H., P., Roger L., J., B., Valerie, Caroline, B., D., and J., B., Robert
558 (2010). A novel social proximity test suggests patterns of social avoidance and gaze aversion-
559 like behavior in BTBR T+ tf/J mice. *Behav Brain Res* 217, 302–8. doi:
560 10.1016/j.bbr.2010.10.033 PMID - 21055421.

561 Banerjee-Basu, S., and Packer, A. (2010). SFARI Gene: an evolving database for the autism
562 research community. *Dis Model Mech* 3, 133–135. doi: 10.1242/dmm.005439.

563 Bannister, A. J., and Kouzarides, T. (2011). Regulation of chromatin by histone modifications.
564 *Nature Publishing Group* 21, 381–395. doi: 10.1038/cr.2011.22.

565 Bustos, F. J., Ampuero, E., Jury, N., Aguilar, R., Falahi, F., Toledo, J., et al. (2017). Epigenetic
566 editing of the Dlg4/PSD95 gene improves cognition in aged and Alzheimer's disease mice.
567 *Brain* 140, 3252–3268. doi: 10.1093/brain/awx272.

568 Bustos, F. J., Pandian, S., Haensgen, H., Zhao, J.-P., Strouf, H., Heidenreich, M., et al. (2023).
569 Removal of a genomic duplication by double-nicking CRISPR restores synaptic transmission
570 and behavior in the MyosinVA mutant mouse Flailer. *Biorxiv*, 2023.04.28.538685. doi:
571 10.1101/2023.04.28.538685.

572 Cenik, B. K., and Shilatifard, A. (2021). COMPASS and SWI/SNF complexes in development
573 and disease. *Nat Rev Genet* 22, 38–58. doi: 10.1038/s41576-020-0278-0.

574 Challis, R. C., Kumar, S. R., Chan, K. Y., Challis, C., Beadle, K., Jang, M. J., et al. (2019).
575 Systemic AAV vectors for widespread and targeted gene delivery in rodents. *Nat Protoc* 14,
576 379–414. doi: 10.1038/s41596-018-0097-3.

577 Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., et al. (2017).
578 Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral
579 nervous systems. *Nature neuroscience* 20, 1172–1179. doi: 10.1038/nn.4593.

580 Chen, C.-H., Huang, A., Huang, Y.-S., and Fang, T.-H. (2021). Identification of a Rare Novel
581 KMT2C Mutation That Presents with Schizophrenia in a Multiplex Family. *J Personalized
582 Medicine* 11, 1254. doi: 10.3390/jpm11121254.

583 Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., et al. (2013). Multiplex Genome
584 Engineering Using CRISPR/Cas Systems. *Science* 339, 819–823. doi:
585 10.1126/science.1231143.

586 Dhaliwal, J., Qiao, Y., Calli, K., Martell, S., Race, S., Chijiwa, C., et al. (2021). Contribution of
587 Multiple Inherited Variants to Autism Spectrum Disorder (ASD) in a Family with 3 Affected
588 Siblings. *Genes-basel* 12, 1053. doi: 10.3390/genes12071053.

589 Eshraghi, A. A., Liu, G., Kay, S.-I. S., Eshraghi, R. S., Mittal, J., Moshiree, B., et al. (2018).
590 Epigenetics and Autism Spectrum Disorder: Is There a Correlation? *Front Cell Neurosci* 12,
591 78. doi: 10.3389/fncel.2018.00078.

592 Fagan, R. J., and Dingwall, A. K. (2019). COMPASS Ascending: Emerging clues regarding the
593 roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. *Cancer Lett* 458, 56–65. doi:
594 10.1016/j.canlet.2019.05.024.

595 Faundes, V., Newman, W. G., Bernardini, L., Canham, N., Clayton-Smith, J., Dallapiccola, B., et
596 al. (2018). Histone Lysine Methylases and Demethylases in the Landscape of Human
597 Developmental Disorders. *Am J Hum Genetics* 102, 175–187. doi:
598 10.1016/j.ajhg.2017.11.013.

599 Gao, Y., Aljazi, M. B., and He, J. (2022). Kdm6b Haploinsufficiency Causes ASD/ADHD-Like
600 Behavioral Deficits in Mice. *Front Behav Neurosci* 16, 905783. doi:
601 10.3389/fnbeh.2022.905783.

602 Gawel, K., Gibula, E., Marszalek-Grabska, M., Filarowska, J., and Kotlinska, J. H. (2019).
603 Assessment of spatial learning and memory in the Barnes maze task in rodents—
604 methodological consideration. *Naunyn-schmiedeberg's Archives Pharmacol* 392, 1–18. doi:
605 10.1007/s00210-018-1589-y.

606 Grove, J., Ripke, S., Als, T. D., Mattheisen, M., Walters, R. K., Won, H., et al. (2019).
607 Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* 51,
608 431–444. doi: 10.1038/s41588-019-0344-8.

609 Henriquez, B., Bustos, F. J., Aguilar, R., Becerra, A., Simon, F., Montecino, M., et al. (2013).
610 Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal
611 neurons. *Molecular and cellular neurosciences* 57, 130–143. doi:
612 10.1016/j.mcn.2013.07.012.

613 Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., et al. (2012). De Novo
614 Gene Disruptions in Children on the Autistic Spectrum. *Neuron* 74, 285–299. doi:
615 10.1016/j.neuron.2012.04.009.

616 Jozwik, K. M., Chernukhin, I., Serandour, A. A., Nagarajan, S., and Carroll, J. S. (2016). FOXA1
617 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase
618 MLL3. *Cell Reports* 17, 2715–2723. doi: 10.1016/j.celrep.2016.11.028.

619 Kim, J.-Y., Grunke, S. D., Levites, Y., Golde, T. E., and Jankowsky, J. L. (2014).
620 Intracerebroventricular Viral Injection of the Neonatal Mouse Brain for Persistent and
621 Widespread Neuronal Transduction. *J Vis Exp*, 51863. doi: 10.3791/51863.

622 Koemans, T. S., Kleefstra, T., Chubak, M. C., Stone, M. H., Reijnders, M. R. F., Munnik, S. de,
623 et al. (2017). Functional convergence of histone methyltransferases EHMT1 and KMT2C
624 involved in intellectual disability and autism spectrum disorder. *Plos Genet* 13, e1006864.
625 doi: 10.1371/journal.pgen.1006864.

626 Lavery, W. J., Barski, A., Wiley, S., Schorry, E. K., and Lindsley, A. W. (2020). KMT2C/D
627 COMPASS complex-associated diseases [KCDCOM-ADs]: an emerging class of congenital
628 regulopathies. *Clin Epigenetics* 12, 10. doi: 10.1186/s13148-019-0802-2.

629 Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., et al. (2020). Autism
630 spectrum disorder. *Nat Rev Dis Primers* 6, 5. doi: 10.1038/s41572-019-0138-4.

631 O'Roak, B. J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B. P., et al. (2012).
632 Sporadic autism exomes reveal a highly interconnected protein network of de novo
633 mutations. *Nature* 485, 246–250. doi: 10.1038/nature10989.

634 Pandian, S., Zhao, J.-P., Murata, Y., Bustos, F. J., Tunca, C., Almeida, R. D., et al. (2020).
635 Myosin Va Brain-Specific Mutation Alters Mouse Behavior and Disrupts Hippocampal
636 Synapses. *Eneuro* 7, ENEURO.0284-20.2020. doi: 10.1523/eneuro.0284-20.2020.

637 Passini, M. A., and Wolfe, J. H. (2001). Widespread Gene Delivery and Structure-Specific
638 Patterns of Expression in the Brain after Intraventricular Injections of Neonatal Mice with an
639 Adeno-Associated Virus Vector. *J Virol* 75, 12382–12392. doi: 10.1128/jvi.75.24.12382-
640 12392.2001.

641 Pitts, M. (2018). Barnes Maze Procedure for Spatial Learning and Memory in Mice. *Bio-protocol*
642 8. doi: 10.21769/bioprotoc.2744.

643 Platt, R. J., Zhou, Y., Slaymaker, I. M., Shetty, A. S., Weisbach, N. R., Kim, J.-A., et al. (2017).
644 Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits. *Cell reports* 19,
645 335–350. doi: 10.1016/j.celrep.2017.03.052.

646 Rubeis, S. D., He, X., Goldberg, A. P., Poultnay, C. S., Samocha, K., Cicek, A. E., et al. (2014).
647 Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 515, 209–215. doi:
648 10.1038/nature13772.

649 Ruthenburg, A. J., Allis, C. D., and Wysocka, J. (2007). Methylation of Lysine 4 on Histone H3:
650 Intricacy of Writing and Reading a Single Epigenetic Mark. *Mol Cell* 25, 15–30. doi:
651 10.1016/j.molcel.2006.12.014.

652 Ruzzo, E. K., Pérez-Cano, L., Jung, J.-Y., Wang, L., Kashef-Haghghi, D., Hartl, C., et al.
653 (2019). Inherited and De Novo Genetic Risk for Autism Impacts Shared Networks. *Cell* 178,
654 850-866.e26. doi: 10.1016/j.cell.2019.07.015.

655 Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., Rubeis, S. D., An, J.-Y., et al.
656 (2020). Large-Scale Exome Sequencing Study Implicates Both Developmental and
657 Functional Changes in the Neurobiology of Autism. *Cell* 180, 568-584.e23. doi:
658 10.1016/j.cell.2019.12.036.

659 Shilatifard, A. (2012). The COMPASS Family of Histone H3K4 Methylases: Mechanisms of
660 Regulation in Development and Disease Pathogenesis. *Annual Review of Biochemistry* 81,
661 65–95. doi: 10.1146/annurev-biochem-051710-134100.

662 Siano, M. A., Maggio, I. D., Petillo, R., Coccidiiferro, D., Agolini, E., Majolo, M., et al. (2022). De
663 Novo Mutation in KMT2C Manifesting as Kleefstra Syndrome 2: Case Report and Literature
664 Review. *Pediatric Reports* 14, 131–139. doi: 10.3390/pediatric14010019.

665 Silverman, J. L., Yang, M., Lord, C., and Crawley, J. N. (2010). Behavioural phenotyping assays
666 for mouse models of autism. *Nat Rev Neurosci* 11, 490–502. doi: 10.1038/nrn2851.

667 Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., and Zhang, F. (2016). Rationally
668 engineered Cas9 nucleases with improved specificity. *Science* 351, 84–88. doi:
669 10.1126/science.aad5227.

670 Stessman, H. A. F., Xiong, B., Coe, B. P., Wang, T., Hoekzema, K., Fenckova, M., et al. (2017).
671 Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and
672 developmental-disability biases. *Nat Genet* 49, 515–526. doi: 10.1038/ng.3792.

673 Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., et al. (2014). In vivo
674 interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nature
675 Biotechnology* 33, 102–106. doi: 10.1038/nbt.3055.

676 Tang, G.-B., Zeng, Y.-Q., Liu, P.-P., Mi, T.-W., Zhang, S.-F., Dai, S.-K., et al. (2017). The
677 Histone H3K27 Demethylase UTX Regulates Synaptic Plasticity and Cognitive Behaviors in
678 Mice. *Front Mol Neurosci* 10, 267. doi: 10.3389/fnmol.2017.00267.

679 Tuncay, I. O., Parmalee, N. L., Khalil, R., Kaur, K., Kumar, A., Jimale, M., et al. (2022). Analysis
680 of recent shared ancestry in a familial cohort identifies coding and noncoding autism
681 spectrum disorder variants. *Npj Genom Medicine* 7, 13. doi: 10.1038/s41525-022-00284-2.

682 V., B., S., W., and J., P. (2007). Assessing autism-like behavior in mice: Variations in social
683 interactions among inbred strains. *Behav Brain Res* 176, 21–26. doi:
684 10.1016/j.bbr.2006.09.007 PMID - 17097158.

685 Wu, D., and Li, R. (2022). Case Report: Long-Term Treatment and Follow-Up of Kleefstra
686 Syndrome-2. *Frontiers Pediatrics* 10, 881838. doi: 10.3389/fped.2022.881838.

687 Zhou, X., Feliciano, P., Shu, C., Wang, T., Astrovskaia, I., Hall, J. B., et al. (2022). Integrating
688 de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-
689 risk genes. *Nat Genet* 54, 1305–1319. doi: 10.1038/s41588-022-01148-2.

690
691
692
693
694

695 FIGURE LEGENDS.

696
697 **Figure 1. Knockout of KMT2C by gene editing *in vitro* and *in vivo*.** (A) Scheme showing the
698 exon 3 of KMT2C genomic sequence and the positions where K1-K2 sgRNA were designed. (B)
699 T7 endonuclease I assay from transduced cultured neurons. (C) RT-qPCR to determine
700 expression levels of KMT2C relative to GAPDH in transduced cultured neurons. (D)
701 Representative image of western blot analysis of total H3 histone, H3K4me3, H3K4me1. (E-F)
702 Quantification of the relative expression of H3K4me3 (E) or H3K4me1 (F). (G) Representative
703 image of brain slice after transduction by intracerebroventricular injection of CRISPR/Cas9. (H)
704 T7 endonuclease I assay from transduced cortical tissue of injected animals. (I) RT-qPCR to
705 determine expression levels of KMT2C relative to GAPDH in transduced cortical tissue of injected
706 animals. Bars represents mean \pm SEM; **p<0.01, ***p<0.001. Students t-test was used to
707 determine significance compared to wild-type condition. Scale bar = 500 μ m.
708

709 **Figure 2. No signs of anxiety behaviors are observed in KMT2C KO animals. (A)** Time on
710 the rotarod apparatus. **(B)** Representative trace plots of open field test in Control and KMT2C KO
711 animals. **(C-F)** Quantification of the total distance travelled **(C)**, time spent in the center area **(D)**,
712 time spent in the periphery **(E)**, and the distance travelled in the center of the open field arena
713 **(F)**. Bars represents mean \pm SEM; **p<0.01. Students t-test, n=14 Control animals and n=9
714 KMT2C KO animals.

715
716 **Figure 3. KMT2C KO animals evidence repetitive behaviors. (A)** Representative trace plots of
717 dark and light test. **(B-C)** Quantification of the number of entries to light zone **(B)**, and the time
718 spent in the light in the dark and light apparatus. **(D)** Representative trace plots of the zero-maze
719 test. **(E-F)** Quantification of the time spent in the open zone **(E)**, and the total distance travelled
720 **(F)** in the zero maze. **(G)** Representative images of the final number of marbles buried by Control
721 and KMT2C KO animals. **(H)** Quantification of the number of marbles buried during the marble
722 burying test. Bars represents mean \pm SEM; *p<0.05. Students t-test, n=14 Control animals and
723 n=9 KMT2C KO animals.

724
725 **Figure 4. Impaired social behaviors of KMT2C KO animals in the 3-chamber test. (A-D)**
726 Quantification of the time spent in the animal's zone **(A)**, the time spent in the object zone **(B)**,
727 the time spent interacting directly with the animal **(C)**, and the time interacting directly with the
728 object **(D)**. Bars represents mean \pm SEM; *p<0.05. Students t-test, n=14 Control animals and n=9
729 KMT2C KO animals.

730
731 **Figure 5. KMT2C KO animals show impaired social interaction behaviors. (A-C)**
732 Quantification of the **(A)** nose-nose (N-N), **(B)** nose-head (N-H), and **(C)** nose-anogenital (N-A)
733 interactions between Control or KMT2C KO animals. **(D)** Quantification of the self-grooming
734 behavior shown by Control or KMT2C KO animals. **(E)** Quantification of the number of victories
735 in the tube dominance test. Bars represents mean \pm SEM; *p<0.05, **p<0.01. Students t-test, n=14
736 Control animals and n=9 KMT2C KO animals.


737
738 **Figure 6. Memory formation is significantly impaired in KMT2C KO animals. (A)** Percentage
739 of time spent freezing by Control and KMT2C animals in the contextual fear conditioning test. **(B)**
740 Quantification of the total distance travelled in the Barnes maze apparatus. **(C)** Primary latency
741 of Control and KMT2C KO animals in the Barnes maze apparatus. **(D)** Quantification of the time
742 spent in the zone of interest where the escape hole was formerly located. Bars represents mean
743 \pm SEM; **p<0.01, ***p<0.001. Students t-test, n=14 Control animals and n=9 KMT2C KO animals.

744


A




B




C




D




E




F




G




H




I







Brauer et al. Figure 2.




Brauer et al. Figure 3.





Brauer et al. Figure 5.



Brauer et al. Figure 6.